Select Page

Category: Health & Medical

FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults

The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment

Read More

Guideline on shorter-course radiation therapy for localized prostate cancer updated

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO’s 2018 recommendations and reflects a matured evidence base showing that shorter-course radiation therapy can maintain cancer control while reducing overall treatment burden for

Read More
Loading